Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of “Buy” from Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given a consensus rating of “Buy” by the six ratings firms that are covering the company, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $17.80.

Several analysts have recently issued reports on the company. Needham & Company LLC reduced their target price on Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 15th. HC Wainwright raised Artiva Biotherapeutics to a “buy” rating and set a $12.00 target price for the company in a research note on Wednesday, June 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ARTV. JPMorgan Chase & Co. lifted its holdings in shares of Artiva Biotherapeutics by 250.7% in the fourth quarter. JPMorgan Chase & Co. now owns 37,619 shares of the company’s stock worth $379,000 after acquiring an additional 26,893 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Artiva Biotherapeutics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock worth $3,184,000 after acquiring an additional 6,828 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Artiva Biotherapeutics by 64.0% in the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares during the last quarter. Barclays PLC increased its stake in shares of Artiva Biotherapeutics by 23.2% in the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock valued at $244,000 after buying an additional 4,545 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Artiva Biotherapeutics by 3.8% in the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after buying an additional 4,335 shares during the period.

Artiva Biotherapeutics Price Performance

ARTV opened at $2.56 on Tuesday. Artiva Biotherapeutics has a 52-week low of $1.47 and a 52-week high of $17.31. The business’s fifty day moving average is $2.20 and its 200-day moving average is $2.94.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Wednesday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.03). On average, research analysts expect that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.